Zotatifin [CAS 2098191-53-6]

Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex[1]. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM) [2]. Zotatifin induces cell apoptosis[1].

[2098191-53-6]

C28H29N3O5

487.55

N#CC1=CC=C([C@@]2(O3)[C@@](C4=C3C=C(OC)N=C4OC)(O)[C@H](O)[C@H](CN(C)C)[C@H]2C5=CC=CC=C5)C=C1

Apoptosis; Eukaryotic Initiation Factor (eIF) ; SARS-CoV

EIF4

10mM

99.69

DMSO : ≥ 100 mg/mL

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature